EU Buys 146M Moderna Doses Without Disclosing Price

European Commission Purchases 146 Million Moderna Doses Without Disclosing Cost

The European Commission has signed a contract to acquire 146 million doses of Moderna's elbichito-19 vaccine for 17 countries, fifteen of which are EU members, including Spain. The official announcement came with a striking omission: the contract amount was not made public. Brussels justifies this as part of its strategy to "improve preparedness and ensure the supply of medical countermeasures" against future health scenarios. However, the figure invites scrutiny: 146 million doses for a European population that has already undergone several rounds of vaccination and, according to coverage data, would hardly absorb such volume.

What the Contract Says and What It Doesn't

The Commission's statement mentions securing supply for participating countries and protecting the most vulnerable. What it does not detail is the unit cost, the total amount, or payment conditions. This opacity has triggered all alarms. In a context of tight budgets and growing scrutiny over public spending, signing an order of this magnitude without figures is, at minimum, an anomaly. Some argue this is standard practice in emergency health contracts; opposing arguments state that the emergency is no longer present and that transparency should be the norm, not the exception.

The Calculation That Doesn't Add Up: 146 Million for 400 Million

Basic arithmetic raises doubts. If the population of the involved countries is around 400 million people and vaccination rates have plummeted after initial campaigns, buying 146 million doses equates to more than a third of the population. For what purpose? Official explanations point to preparation for new variants, but the reality is that citizen demand has collapsed. As one frequently repeated intervention summarizes: "The business is in the purchase, not in its use." The phrase, attributed to a participant, condenses widespread skepticism.

Business Before Health: Who Benefits From This?

Focus has shifted to the economic beneficiary. Moderna, the awarded pharmaceutical company, saw revenues soar during the pandemic and now secures million-dollar orders years in advance. The Commission, for its part, acts as an intermediary in an operation some describe as a windfall. The shadow of corruption looms over the file: there are no formal accusations, but the lack of transparency fuels all kinds of suspicions. It is argued that money "has changed hands, from ours to theirs," and that the cycle closes without citizens seeing a clear return.

Trust in Institutions at Rock Bottom

Wear is evident. Vaccination intention surveys show a sustained decline, not only for elbichito but also extending to other routine vaccines. The mass purchase is interpreted as an attempt to force demand through supply. "They become mandatory by law and that's it," points out one of the most cited voices. Distrust no longer distinguishes between national governments and Brussels: the perception of a shared hidden agenda gains ground in critical circles.

Conspiracy Theories and Their Role in the Debate

Alongside reasonable criticism, the issue has dragged a procession of theories lacking evidentiary support. There is talk of "radio-modulable nanotechnology for mind control," selective depopulation plans, and satanic pacts. These claims, repeated jokingly or as denunciations, have no evidence and contaminate a debate that, at its core, raises legitimate questions about public spending, transparency, and health priorities. Mixing solid arguments with fabrications makes it difficult to distinguish founded criticism from noise.

What Remains Unknown

The contract is signed, but questions remain unanswered. How much was paid per dose? What confidentiality clauses shield it? Is the volume justified by current epidemiological data? The Commission has offered no details, and national parliaments, including Spain's, have not announced investigations. Opacity, in this case, is not an administrative detail: it is the center of the problem. Until these unknowns are cleared, suspicion will continue to occupy the space that information should fill.